Real-world clinical outcomes of patients (pts) with metastatic renal cell carcinoma (mRCC) in current immune-oncology (IO) and tyrosine kinase inhibitors (TKIs) era.

被引：0
|
作者：
Shah, Neil J.
Sura, Sneha
Shinde, Reshma
Shi, Junxin
Perini, Rodolfo F.
Puneet, Singhal
Robert, Nicholas J.
Vogelzang, Nicholas J.
Motzer, Robert J.
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] Ontada, Irving, TX USA
[3] Merck & Co Inc, Kenilworth, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 06期
关键词：
D O I：
10.1200/JCO.2022.40.6_suppl.331
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
331
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Real-world outcomes among patients with advanced/metastatic renal cell carcinoma (mRCC) treated with tyrosine kinase inhibitors (TKls) monotherapy or TKI-IO combination therapy
    Dong, Pei
    Huang, Tingxuan
    Peng, Yulu
    Wei, Wensu
    Jiang, Lijuan
    Zhong, Xi
    Zhang, Zhiling
    Han, Hui
    Zhou, Fangjian
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [2] Real-world (RW) clinical outcomes for metastatic renal cell carcinoma (mRCC)
    George, S.
    Faccone, J.
    Huo, S.
    Zhang, Y.
    Stwalley, B.
    Hamilton, M.
    Le, T. K.
    Ejzykowicz, F.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S701 - S702
  • [3] Real-world outcomes among patients with advanced/metastatic renal cell carcinoma (mRCC) treated with cabozantinib or other tyrosine kinase inhibitors (TKIs) after checkpoint inhibitor (CPI) therapy.
    Heng, Daniel Yick Chin
    Doshi, Gury K.
    Dutailly, Pascale
    Houchard, Aude
    Lothgren, Mickael
    Monnette, Alisha
    Wang, Yunfei
    Perrot, Valerie
    Lalani, Aly-Khan A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [4] Clinical outcome of patients (Pts) with metastatic renal cell carcinoma (mRCC) progressing on front-line immune-oncology based combination (IO-COMBO) regimens.
    Barata, Pedro C.
    de Liano, Alfonso Gomez
    Mendiratta, Prateek
    Crolley, Valerie
    Szabados, Bernadett
    Wood, Laura S.
    Zanick, Beth
    Allman, Kimberly D.
    Tyler, Allison Janine
    Martin, Allison
    Gilligan, Timothy D.
    Grivas, Petros
    Ornstein, Moshe Chaim
    Garcia, Jorge A.
    Powles, Thomas
    Rini, Brian I.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [5] Real-world treatment patterns and clinical outcomes of metastatic renal cell carcinoma patients post immune-oncology (IO) and Vascular Endothelial Growth Factor (VEGF) receptor targeted therapies
    Shah, Neil
    Sura, Sneha
    Shinde, Reshma
    Wentworth, Chuck
    Conkling, Paul
    Bupathi, Manojkumar
    Perini, Rodolfo
    Vickery, Donna
    Motzer, Robert
    [J]. ONCOLOGIST, 2024, 29 : S22 - S23
  • [6] A real-world experience of immune checkpoint inhibitors (ICI) in metastatic renal cell carcinoma (mRCC)
    Elias, Roy
    Levonyak, Nicholas
    Christie, Alana
    Bowman, Isaac Alexander
    Kapur, Payal
    Hannan, Raquibul
    Hammers, Hans J.
    Brugarolas, James
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [7] Real-world Outcomes of Tyrosine Kinase Inhibitors Immediately After Immune Checkpoint Inhibitors in Renal Cell Carcinoma
    Kato, Taigo
    Nagahara, Akira
    Kawamura, Norihiko
    Nakata, Wataru
    Soda, Tetsuji
    Matsuzaki, Kyosuke
    Hatano, Koji
    Kawashima, Atsunari
    Ujike, Takeshi
    Imamura, Ryoichi
    Nishimura, Kensaku
    Takada, Shingo
    Tsujihata, Masao
    Yamaguchi, Seiji
    Takao, Tetsuya
    Nakai, Yasutomo
    Nakayama, Masashi
    Nonomura, Norio
    Uemura, Motohide
    [J]. ANTICANCER RESEARCH, 2021, 41 (11) : 5811 - 5816
  • [8] Hypogonadism in men treated with tyrosine kinase inhibitors (TKIs) for metastatic renal cell carcinoma (mRCC) as a clinical biomarker of response
    Afshar, Mehran
    Clarke, Helen
    Porfiri, Emilio
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [9] Real-world utilization and outcomes of immune-based combination therapies or tyrosine kinase inhibitors (TKIs) for advanced renal cell carcinoma (aRCC)
    Geynisman, D.
    Kish, J. K.
    Falkenstein, A.
    Del Tejo, V.
    Stwalley, B.
    Huo, S.
    Balanean, A.
    Feinberg, B. A.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S702 - S702
  • [10] Incidence and severity of hypothyroidism and survival outcomes in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors (TKIs).
    Bailey, Erin B.
    Tantravahi, Srinivas Kiran
    Wells, Chesley E.
    Straubhar, Alli M.
    Batten, Julia A.
    Poole, Austin
    Stenehjem, David D.
    Agarwal, Neeraj
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345